ViroPharma Inc (VPHM.OQ)

VPHM.OQ on NASDAQ Stock Exchange Global Select Market

32.45USD
1 Aug 2013
Price Change (% chg)

$-1.87 (-5.45%)
Prev Close
$34.32
Open
$32.70
Day's High
$32.75
Day's Low
$31.40
Volume
235,716
Avg. Vol
221,894
52-wk High
$35.18
52-wk Low
$19.59

VPHM.OQ

Chart for VPHM.OQ

About

ViroPharma Incorporated (ViroPharma) is an international biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare... (more)

Overall

Beta: 1.71
Market Cap (Mil.): $2,241.48
Shares Outstanding (Mil.): 65.31
Dividend: --
Yield (%): --

Financials

  VPHM.OQ Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -1.19 -- --
ROI: -7.02 -2.58 18.76
ROE: -9.93 -2.66 19.59
Search Stocks

Niche drugmaker ViroPharma attracts takeover interest: sources

NEW YORK - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.

19 Jun 2013

CORRECTED-UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest - sources

(In June 17 item, corrects in 3rd paragraph to show that ViroPharma is 19 years old)

19 Jun 2013

Niche drugmaker ViroPharma attracts takeover interest: sources

NEW YORK - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.

17 Jun 2013

UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest -sources

NEW YORK, June 17 - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.

17 Jun 2013

Orphan drugmaker ViroPharma attracts takeover interest -sources

NEW YORK, June 17 - ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.

17 Jun 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$495.00
Provider: S&P Capital IQ Factual Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks